![DRUG PROFILE
Name: Omeprazole
Brand Names Prilosec and Losec
Molecular Weight: 345.42 g/mol
Chemical Formula: C17H19N3O3S
Structure:
IUPAC Name: 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H- benzimidazole](https://image.slidesharecdn.com/formulationandevaluationofomeprazolefloatingtablets-170207133527/85/Formulation-and-evaluation-of-omeprazole-floating-tablets-8-320.jpg)
Formulation and evaluation of omeprazole floating tablets
- 1. FORMULATION AND EVALUATION OF OMEPRAZOLE FLOATING TABLETS Dr chandra
- 2. CONTENTS Introduction Literature Review Aim and Objectives Material and Methods Results and Discussion Conclusion References
- 3. INTRODUCTION Floating tablets: Floating systems (or) hydro-dynamically balanced systems have a bulk density lower than gastric fluid and thus remain buoyant in the stomach without affecting the gastric emptying rate for a prolonged period of time. While the system is floating on the gastric contents, the drug is slowly released at a desired rate from the stomach. After the release of drug, the residual system is emptied from the stomach. This result in an increase in the gastric retention time and better control of fluctuations in the plasma drug concentration
- 4. ADVANTAGES The Gastroretentive systems are advantageous for drugs absorbed through the stomach. Irritation on the stomach wall caused by acidic substances like aspirin can be avoided by using floating drug delivery system. The Gastroretentive systems are advantageous for drugs meant for local action in the stomach When there is a vigorous intestinal movement and a short transit time as might occur in certain type of diarrhea, poor absorption is expected. Under such circumstances it may be advantageous to keep the drug in floating condition in stomach to get a relatively better response
- 5. DISADVANTAGES Floating system is not feasible for those drugs that have solubility or stability problem in the G.I. tract. These systems require a high level of fluid in the stomach for drug delivery to float and work efficiently. The drugs that are significantly absorbed throughout the gastrointestinal tract, which undergo significant first pass metabolism, are only desirable candidate. Some drugs present in the floating system causes irritation to the gastric mucosa.
- 6. LITERATURE REVIEW Raguia Ali Shoukri et. al studied on “Formulation and in vitro evaluation of combined floating mucoadesive tablet of Omeprazole succinate”. Floating mucoadhesive tablet of Omeprazole succinate were developed to prolong its release and improve bioavailability and avoidance of first pass hepatic metabolism. Floating tablets were prepared by directly compressible polymer such as hydroxyl propyl methyl cellulose (HPMC) K4M, HPMC K15M, sodium carboxyl methyl cellulose and carbopol 940P and were evaluated for buoyancy test, mucoadhesion force, swelling study, drug content, Ex vivo mucoadhesion strength and in vivo release profile. Gupta S.C et. al studied on “Development and in-vitro dissolution studies of bilayer tablet of Omeprazole succinate (SR) and Hydrochlorothiazide (IR)”. In the immediate release formulation micro crystalline cellulose and starch were used as super disintegrant and was directly compressed. For sustained release portion HPMC polymers were used. The compressed bilayer tablets were evaluated for weight variation, thickness, hardness, friability, drug content, and in-vitro drug release using USP dissolution apparatus type-2 (paddle) by using HPLC method. Drug release from the matrix was found to decrease with increase in polymer concentration in intra and extra granulation, where the polymer concentration was employed from 20-50%w/w of the average tablet weight. Tanmoy ghosh et. al. Studied on “Formulation and evaluation of sustained release Omeprazole succinate matrix tablets by direct compression process using kollidon SR”. Sustained release matrix tablets were prepared by different concentrations of directly compressible grade and controlled release polymer of kollidon SR. Finally concluded that kollidon SR can be utilized for effective production of controlled release Omeprazole Succinate matrix tablets by direct compression process using an optimum concentration for desired release profile.
- 7. LITERATURE REVIEW Ozturk AG et. al 51: studied on “Fabrication and in vitro evaluation of porous osmotic pump based controlled drug delivery of Omeprazole succinate”. The purpose of investigation was that an osmotically controlled oral drug delivery system utilizes osmotic pressure for controlled delivery of active agents. The osmotic control release of tablet was prepared by two different approaches; one using an osmotic agent and another using a swelling agent. The effect of concentration of osmotic agent and swelling agent on in vitro release was studied and was found that drug release depend on both these factors. Narisawa S et. al 52: studied on “Formulation and evaluation of Omeprazole succinate controlled release tablets using natural and synthetic polymer”. The objective of the present study is to develop controlled release tablets of Omeprazole succinate using natural polymer-guar gum and synthetic polymer-carbopol as a rate controlling polymers for treatment of hypertension, angina pectoris, cardiac arrthymias. It was also desired to study the effect of polymer concentration. The formulations are made by employing the conventional wet granulation method, to achieve prolonged release of medicaments. The formulation containing 5% carbopol-934 released 89% of the drug in 12hours.
- 8. DRUG PROFILE Name: Omeprazole Brand Names Prilosec and Losec Molecular Weight: 345.42 g/mol Chemical Formula: C17H19N3O3S Structure: IUPAC Name: 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H- benzimidazole
- 9. Description: This is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL receptors, it increases breakdown of LDL cholesterol. Drug category: gastroesophageal reflux disease, peptic ulcer disease, and Zollinger–Ellison syndrome Omeprazole (Prilosec, Zegerid) belongs to group of drugs called proton pump inhibitors. It decreases the amount of acid produced in the stomach. Omeprazole is used to treat symptoms of Gastro Esophageal Reflux Disease (GERD) and other conditions caused by excess stomach acid. It is also used to promote healing of erosive esophagitis (damage to your esophagus caused by stomach acid). Omeprazole may also be given together with antibiotics to treat gastric ulcer caused by infection with helicobacter pylori (H. pylori). Omeprazole is not for immediate relief of heartburn symptoms.
- 10. AIM AND OBJECTIVES o The present project is proposed to formulation and evaluation of omeprazole floating tablets. o Omeprazole used in combination with antacids promotes local delivery of these drugs to the receptor of the parietal cell wall. Local delivery also increases the stomach wall receptor site bioavailability and increases the drugs’ ability to reduce acid secretion. The objectives of the present investigations are: To carry out an extensive literature review on omeprazole formulations. To perform pre-formulation studies and to check whether the drug is suitable for direct compression technique. To characterization of developed tablets for hardness, thickness, weight variation, dimensions, etc., To optimize the best formulation based on the statistical optimization. To optimize a safe, effective and stable dosage form of omeprazole floating tablets. The stability data of the optimized formulation indicated that the formulation showed sufficient stability upon storage.
- 11. PLAN OF WORK It was planned to carryout study in the sequences below: Extensive literature review Formulation and evaluation of omeprazole floating tablets. Formulation and evaluation of omeprazole floating tablets. -Angle of repose -Bulk density -Tapped density Evaluation of Post compression characteristics of omeprazole of floating tablets. -Hardness - -Friability Weight variation Selection of best formulation on the basis of evaluation of omeprazole floating tablets.
- 12. MATERIALS AND METHODS List of Equipments Equipment Company Electronic Balance MettlerToledo, USA B.D. Apparatus Cambell electronics’, Mumbai UV-Vis Spectrophotometer LabIndia Tablet Compression Machine Jaguarl Machinery Company, Mumbai Friability Test Apparatus USP23 Roche Friabilator LabIndia, Mumbai Tablet Hardness Tester Stokes Monsanto Hardness Tester,
- 13. Composition of different floating tablet formulations of Omeprozole: Formulation code F1 F2 F3 F4 F5 F6 Ingredients(mg) Omeprazole 40 40 40 40 40 40 HPMC K 4 M 80 80 - - 40 40 HPMC K 15 M - - 80 80 40 40 Sodium bicarbonate 20 10 20 10 20 10 Mg. Stearate 2 2 2 2 2 2 Lactose 20 20 20 20 20 20 Talc 2 2 2 2 2 2 PVK-30 30 30 30 30 30 30 Citric acid 10 20 10 20 10 20
- 14. Preparation of Floating Tablets : Effervescent Floating tablets containing Omeprazole were prepared by direct compression technique using varying concentrations of different grades of polymers (HPMC K4 M and HPMC K15 M) with sodium bicarbonate and citric acid. All the ingredients were accurately weighed as show in Table and passed through different mesh sieves accordingly. Then, except Magnesium stearate and talc all other ingredients were blended uniformly in glass mortar After sufficient mixing of drug as well as other components, Magnesium stearate and talc was added, as post lubricant, and further mixed for additional 2-3 minutes. The blend was characterized for the different physical parameters such as bulk density, Tapped density. The tablets were compressed using rotary tablet machine. The weights of the tablets were kept constant for all formulation. Tablets were compressed at 200 mg weight.
- 15. PRECOMPRESSIONAL PARAMETERS Bulk density Tapped density Carr’s index Hausner’s ratio Angle of repose ()
- 16. POST COMPRESSIONAL PARAMETERS 1 Weight variation 2 Hardness 3 Friability 4 Content uniformity 5 In-Vitro Dissolution.
- 17. RESULTS AND DISCUSSION Precompressional parameters Formulation code/Parameter Bulk density Tapped density Angle of repose Compressib ility index Hausners ratio F1 0.55 0.65 28.5 15.5 1.02 F2 0.45 0.67 26.5 17.5 1.05 F3 0.51 0.71 29.5 19.8 1.10 F4 0.52 0.65 28.9 16.4 1.03 F5 0.49 0.70 26.6 15.6 1.15 F6 0.52 0.66 30.5 16.9 1.23
- 18. Post compressional parameters Formulation code/Parameter Hardness Weight variation Friability Drug content (%) F1 3.8 Pass 0.54 91.3 F2 3.74 Pass 0.75 90.6 F3 3.95 Pass 0.64 96.0 F4 3.7 Pass 0.44 96.6 F5 3.9 Pass 0.77 91.33 F6 3.6 Pass 0.65 95.3
- 19. Batch 1hr 2hr 3hr 4hr 5hr 6hr 7hr F1 17.95 23.30 38.90 48.81 61.70 86.88 91.79 F2 23.92 28.90 35.88 48.85 65.78 83.72 90.69 F3 15.94 25.91 43.85 55.81 61.69 72.75 88.70 F4 21.92 37.87 43.80 62.69 68.77 76.74 83.72 F5 23.82 30.89 41.86 58.80 63.78 80.73 85.71 F6 19.93 31.89 53.82 58.80 62.79 73.75 94.68 Cumulative % drug released of F1 to F7 (0.1N HCl) Formulation InVitro drug Release
- 20. 0 10 20 30 40 50 60 70 80 90 100 1hr 2hr 3hr 4hr 5hr 6hr 7hr %DrugRelease Time(Hrs) F1 F2 F3 F4 F5 F6 Cumulative drug release F1-F6
- 21. DRUG RELEASE KINETICS Zero order Frist order Highuchi peppas F.CODE R2 R2 R2 R2 F1 0.9839 0.9337 0.9766 0.9775 F2 0.9896 0.8732 0.9086 0.982 F3 0.8047 0.9683 0.9335 0.969 F4 0.885 0.9656 0.9807 0.9828 F5 0.9105 0.982 0.9807 0.9854 F6 0.8583 0.9931 0.9539 0.9618
- 22. Conclusion
- 23. REFERENCES o Senel S, Capan Y, Dalkara T, Tnanç N, Hincal A. A formulation, bioavailability, and pharmacokinetics of sustained-release potassium chloride tablets. Pharm Res.1991;8(10):1313-7(5). o Farid DJ, Sadeg SN, Hassani M, Nokhodchy A. Sustained release formulations of nifedipine. Ind J Pharm Sci 1998;6:375-8. o Simler, R., Walsh, G., Mattaliano, R.J., Guziewicz, N., and Perez-Ramirez, B. (2008). Maximizing Data Collection and Analysis During Preformulation of Biotherapeutic Proteins. BioProcess International 6(10), 38-45. o Prabhakarareddy V, Suneeta A. Release rate of diclofenac sodium from different polymers. Ind J Pharm Sci 2000;4:313-6. o Chang, B.S. and Hershenson, S. 2002. Practical approaches to protein formulation development. in "Rationale Design of stable protein formulations-theory and practice" (J.F. Carpenter and M.C. Manning eds.) Kluwer Academic/Plenum publishers, New York, pp. 1-25. o Rationale Design of Stable Lyophilized Protein Formulations: Some Practical Advice, Carpenter et al, Pharmaceutical Research, Vol 14, No.8, 1977. o http://en.wikipedia.org/wiki/Formulations o K Shobhit kumar *, Satish kumar gupta, et.al Dissolution o Rate enhancement of aceclofenac by solid dispersion technique , ISSN2231-442304 o G.Sainath, A. Mamatha Sree, J. Subba Rao AnInternational Journal Of Advances In Pharmaceutical Sciences Volume 4, Issue 1, January-February 2013,Pages94-1 o J.Kaur, G Aggrawal, G .singh, A.C.Rana .Improvement of drug solubility using solid dispersion. Int .j. pharm .Sci .,2012,4:50 o A.Luhadiya, S.Agrawal, P.Jain, P.K.Dubey A review on solid dispersion. int .j .Adv .Res Pharm.biol Sci. 2012,1:281-291 .
- 24. John W. Skoug, , Martin V. Mikelsons, Cynthia N. Vigneronand Nick L. Stemm “Qualitative evaluation of the mechanism of release of matrix sustained release dosage forms by measurement of polymer release” Control Development, April-1993. Ayhan Savaşer, Yalçın Özkan, and Aşkın Işımer, “Preparation and in vitro evaluation of sustained release tablet formulations of diclofenac sodium” Department of Pharmaceutical Technology, Gülhane Military Medical Academy, Etlik, 06018 Ankara, Turkey. October-2008. P.G.Yeole, U.C.Galgatte, I.B.Babla, “Design and evaluation of xanthan gum based sustained release matrix tablets of diclofenac sodium” International Journal of pharmaceutical sciences.2006, pg 185-189. D.M. Morkhade, S.V. Fulzele, “Gum Copal and Gum Damar: Novel Matrix forming Materials for Sustained Drug delivery”, International Journal of pharmaceutical sciences.2006, pg 53-58. Eshwar, Ayesha, “introduction of sustained release Opipramol Di hydrochloride matrix tablets as a new approach in the treatment of depressive disorders”, International Journal of Biomedical science, 2006, 2, (4), pg 337-343. A.K.Srivastava, Saurabh wadhwa, B.mishra, “oral sustained delivery of Atenolol from floating matrix tablets - formulation and in vitro evaluation.” Drug development and industrial pharmacy, 2005, 31, (4-5), pg 367-374. Neal M.Davies, “sustained release and enteric coated NSAIDS: Are they really GI safe?”, J pharm pharmaceut sci, 1999, 2, (1), pg 5-14. Mohammad Reza Siahi, Mohammad Barzegar-Jalali, Farnaz Monajjemzadeh, “Design and Evaluation of 1- and 3-Layer Matrices of Verapamil Hydrochloride for Sustaining Its Release”. AAPS PharmSciTech. 2005; 6(4): E626-E632. Mohammad Siahi, Mohammad Barzegar-Jalali, Farnaz Monajjemzadeh, Fatemeh Ghaffari Shirzad Azarmi , “Design and evaluation of 1- and 3-layer matrices of verapamil hydrochloride for sustaining its release”, AAPS PharmSciTech. 2005; 6(4): E626-E632. www.medicinefda.com Giovanna Corti, Marzia Cirri, Francesca Maestrelli, Natascia Mennini, “Sustained-release matrix tablets of metformin hydrochloride in combination with triacetyl-β-cyclodextrin”Europian Journal of pharmaceutics and biopharmaceutics 2008, 68, (2), pg 303-309.